Role of Serum Regucalcin in Diagnosis of HCC Clinical Trial
Official title:
Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma
Although the diagnosis and therapy of HCC have being improved, the poor prognosis still
remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it
is important to detect the protein biomarkers which are associated with HCC tumor progression
and may be useful as potential diagnosis or therapeutic targets.
SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identiļ¬ed
from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular
carcinoma associated antigens [4]
Serum antibody response to SMP30 in various patients using the methods of Western-blot and
ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in
the one with alpha-fetoprotein (AFP) negative
n/a